Publications by authors named "M Hirao"

This report describes two cases of implant-stable traumatic periprosthetic fractures after total ankle arthroplasty (TAA) in patients with rheumatoid arthritis (RA). One case with low body mass index (BMI) [14 kg/m2] achieved complete bone union with the use of an external fixator, while the other case with a high BMI [32.83 kg/m2] failed to achieve bone union with the external fixator; however, complete union was achieved utilizing secondary internal plate fixation.

View Article and Find Full Text PDF

This report describes the case of an 85-year-old woman who was found to have seronegative rheumatoid arthritis during preoperative investigations for knee replacement surgery for osteoarthritis. Follow-up for knee osteoarthritis was continued for many years without any symptoms involving other joints. Before total knee arthroplasty for osteoarthritis, preoperative investigations revealed a highly inflammatory state.

View Article and Find Full Text PDF

Background/aim: Chemoresistance to paclitaxel (PTX) significantly ameliorates therapeutic efficacy in patients with non-small cell lung cancer (NSCLC), especially in advanced stages, deteriorating the progression free and overall survival rates. One of the critical mechanisms contributing to drug resistance is the excretion of PTX from target cells via efflux pumps. Ivermectin was developed as a bactericidal agent against parasites; however, it has recently been shown to inhibit the proliferation of human cancer cells.

View Article and Find Full Text PDF

Background: Generally, scarf osteotomy is recommended for moderate-severe hallux valgus (HV) deformity. Although severe HV deformity is defined to be more than 40 degree (°), this definition of angular setting includes broad range of HV angle (HVA). Actually, very severe HV deformity such as more than 60° of the HVA is often seen.

View Article and Find Full Text PDF

Background: Esophageal cancer is one of the most common types of cancer in Japan. Herein, we report the efficacy and safety of E7389-LF plus the immune checkpoint inhibitor, nivolumab, from the esophageal cancer cohort of the phase 2 part of Study 120.

Methods: Eligible patients received E7389-LF 2.

View Article and Find Full Text PDF